101 related articles for article (PubMed ID: 15951470)
21. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
Marbury T; Dowell JA; Seltzer E; Buckwalter M
J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
23. FTY720 pharmacokinetics in mild to moderate hepatic impairment.
Kovarik JM; Schmouder RL; Serra D; Wang Y; Wiegand H; Dilzer SC; Lasseter KC
J Clin Pharmacol; 2005 Apr; 45(4):446-52. PubMed ID: 15778425
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacokinetics of ranolazine.
Jerling M
Clin Pharmacokinet; 2006; 45(5):469-91. PubMed ID: 16640453
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
[TBL] [Abstract][Full Text] [Related]
27. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers.
Shah J; Wesnes KA; Kovelesky RA; Henney HR
Clin Ther; 2006 Sep; 28(9):1308-17. PubMed ID: 17062304
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of oral tonapofylline and its acyl-glucuronide metabolite in patients with mild and moderate hepatic impairment.
Li Z; Gan LS; Marbury T; Lasseter KC; Natarajan A; Stecher S; Wei D; Yang L; Freedman D; Deykin A
J Clin Pharmacol; 2012 Apr; 52(4):543-51. PubMed ID: 21610206
[TBL] [Abstract][Full Text] [Related]
29. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry.
Penman AD; Eadie J; Herron WJ; Reilly MA; Rush WR; Liu Y
Rapid Commun Mass Spectrom; 1995; 9(14):1418-30. PubMed ID: 8534891
[TBL] [Abstract][Full Text] [Related]
30. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients.
Gelone DK; Park JM; Lake KD
Pharmacotherapy; 2007 Sep; 27(9):1272-8. PubMed ID: 17723081
[TBL] [Abstract][Full Text] [Related]
31. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.
Small DS; Wrishko RE; Ernest CS; Ni L; Winters KJ; Farid NA; Li YG; Brandt JT; Salazar DE; Borel AG; Kles KA; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):585-94. PubMed ID: 19744014
[TBL] [Abstract][Full Text] [Related]
32. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
33. Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Pharmacol Drug Dev; 2016 Mar; 5(2):141-9. PubMed ID: 27138027
[TBL] [Abstract][Full Text] [Related]
34. Sensitive quantification of ranolazine in human plasma by liquid chromatography--tandem mass spectrometry with positive electrospray ionization.
Tian L; Jiang J; Huang Y; Hua L; Liu H; Li Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 846(1-2):346-50. PubMed ID: 16959552
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
Peng JZ; Pulido F; Causemaker SJ; Li J; Lorenzo A; Cepeda C; García Cabanillas JA; DaSilva B; Brun SC; Arribas J
J Clin Pharmacol; 2006 Mar; 46(3):265-74. PubMed ID: 16490802
[TBL] [Abstract][Full Text] [Related]
36. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker.
Falcão A; Maia J; Almeida L; Mazur D; Gellert M; Soares-da-Silva P
Biopharm Drug Dispos; 2007 Jul; 28(5):249-56. PubMed ID: 17443646
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Koren MJ; Crager MR; Sweeney M
J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
39. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
Horak J; White J; Harris AL; Verrill M; Carmichael J; Holt A; Cantarini M; Macpherson M; Swaisland A; Swaisland H; Twelves C
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1485-95. PubMed ID: 21487718
[TBL] [Abstract][Full Text] [Related]
40. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]